Results 31 to 40 of about 775,670 (354)

EGFR in Limbo [PDF]

Cell, 2012
The epidermal growth factor receptor (EGFR) is normally activated by ligand-induced dimerization. Oncogenic mutations in EGFR promote activation in a largely ligand-independent manner. Shan et al. uncover a partially disordered state of EGFR kinase, providing evidence that oncogenic mutations counteract this intrinsic structural instability to promote ...
Eck, Michael J., Hahn, William C.
openaire   +2 more sources

Blockade of Radiation-induced EGFR Nuclear Transport Enhances Radiosensitivity of Human Cervical Cancer

Zhongliu Fangzhi Yanjiu, 2020
Objective To investigate whether the inhibition of EGFR nuclear transport could reduce the radioresistance of human cervical cancer cells. Methods Human cervical cancer CaSki and HeLa cells were exposed to radiation treated with or without Thr654 ...
LI Lu, HUANG Jianming, FENG Mei, QI Yunxiang, MA Shiqi, TAN Mingyu, LANG Jinyi   +6 more
doaj   +1 more source

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. [PDF]

, 2019
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance.
A Hübner, AB D’Assoro, AJ Lee, AN Hata, Andrei Goga, Andrew D. Simmons, Angel Ku, AS Nikonova, Ashley Maynard, B Melichar, CA Eberlein, CK Lee, CM Blakely, CM Blakely, Collin M. Blakely, D Ercan, DB Costa, F Varghese, Frank McCormick, Golzar Hemmati, Gregor Krings, Hayley J. Donnella, Henry J. Haringsma, J Chen, J Fu, Jacqueline Galeas, JJ Chabon, Jonathan Kuhn, Julia Rohrberg, Julia Rotow, K Shien, Khyati N. Shah, KS Thress, L Li, Liliane Robillard, LV Sequist, LV Sequist, M Moustafa-Kamal, M Ramirez, Maria M. Martins, MJ Niederst, MS Cragg, MW Karaman, OJ Gruss, PA Jänne, R Rosell, RA Burrell, Roma Bhatt, S Anand, S Stewart, Sophie Dumont, Sourav Bandyopadhyay, SV Sharma, Swati Kaushik, T Sharifnia, TC Chou, TG Bivona, TG Bivona, Thomas C. Harding, TM Kim, Trever G. Bivona, V Bavetsias, Victor Olivas, Victoria E. Wang, Y Zhou, Z Piotrowska, Z Yang   +66 more
core   +1 more source

Canine parvovirus induces G1/S cell cycle arrest that involves EGFR Tyr1086 phosphorylation

Virulence, 2020
Canine parvovirus (CPV) has been used in cancer control as a drug delivery vehicle or anti-tumor reagent due to its multiple natural advantages. However, potential host cell cycle arrest induced by virus infection may impose a big challenge to CPV ...
Xiaofeng Dai, Xuanhao Zhang, Yujie Miao, Peiyu Han, Jianying Zhang   +4 more
doaj   +1 more source

NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. [PDF]

, 2018
Notch dysregulation has been implicated in numerous tumors, including triple-negative breast cancer (TNBC), which is the breast cancer subtype with the worst clinical outcome.
Bellavia, Diana, Besharat, ZEIN MERSINI, Capalbo, Carlo, Checquolo, Saula, D'Amati, Giulia, Del Gaudio, Francesca, Diluvio, Giulia, Franciosa, Giulia, Giuli, MARIA VALERIA, Giuliani, Eugenia, Maroder, Marella, Palermo, Rocco, Pignataro, MARIA GEMMA, Talora, Claudio, Vacca, Alessandra   +14 more
core   +2 more sources

The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR [PDF]

, 2015
Purpose: Identification of critical genes which play pivotal roles in controlling tumor growth and survival will establish the basis for developing therapeutic targets. In this study, we focused on frequencies of EGFR, ErbB2 and MET gene amplification in
Farazmandfar, T., Janbabai, G., Naghshvar, F., Oladi, Z., Taghvaei, T.   +4 more
core   +1 more source

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

Cancer Research, Statistics, and Treatment, 2019
Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic chemotherapy, which resulted in a median overall survival of 7.9 months.
Akhil Rajendra, Vanita Noronha, Amit Joshi, Vijay Maruti Patil, Nandini Menon, Kumar Prabhash   +5 more
doaj   +1 more source

Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer [PDF]

, 2016
Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-driven lung cancer, but their clinical impact is often impaired by acquired drug resistance through the secondary T790M EGFR mutation.
Chater, E, De Bruin, E, Downward, J, Heynen, GJJE, Hu, Y, Li, H, Liu, Z, Pardo, OE, Roy, R, Seckl, MJS, Smit, EF, Stokes, W, Tang, H, Wang, Y   +13 more
core   +2 more sources

Study of EGFR expression in tumor tissue in patients with locally advanced oral cavity cancer receiving cetuximab therapy

Медицинский совет, 2020
Introduction: Squamous cell carcinoma of the oral cavity is one of the most common head and neck cancers with an aggressive course and high mortality rates.
A. A. Lyanova, L. Yu. Vladimirova, E. P. Ulianova, A. E. Storozhakova, N. A. Abramova, I. L. Popova, M. A. Teplyakova, N. M. Tikhanovskaya, V. S. Myagkova, K. A. Novoselova, L. A. Ryadinskaya, L. K. Strakhova, E. A. Kalabanova   +12 more
doaj   +1 more source

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

PLoS Medicine, 2005
Background Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor ...
W. Pao, V. Miller, K. Politi, Gregory Riely, R. Somwar, M. Zakowski, M. Kris, H. Varmus   +7 more
semanticscholar   +1 more source